The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica.
Anti-Inflammatory Agents, Non-Steroidal
Clinical Laboratory Techniques
Diagnostic Imaging
/ methods
Europe
Exercise Therapy
Follow-Up Studies
Glucocorticoids
/ administration & dosage
Humans
Immunosuppressive Agents
/ therapeutic use
Italy
Methotrexate
/ therapeutic use
Polymyalgia Rheumatica
/ diagnosis
Referral and Consultation
Rheumatology
/ standards
Societies, Medical
Stakeholder Participation
Journal
Reumatismo
ISSN: 0048-7449
Titre abrégé: Reumatismo
Pays: Italy
ID NLM: 0401302
Informations de publication
Date de publication:
10 Apr 2020
10 Apr 2020
Historique:
received:
13
12
2019
accepted:
21
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
24
3
2021
Statut:
epublish
Résumé
to provide evidence-based up-to-date recommendations for the management of patients with a definite diagnosis of polymyalgia rheumatica (PMR). A systematic literature review was performed to find the existing clinical practice guidelines (CPGs) on PMR and the framework of the Guidelines International Network Adaptation Working Group was used to appraise (AGREE II), synthesize, and customize the recommendations according to the needs of the Italian healthcare context. Rheumatologists on behalf of the Italian Society of Rheumatology (SIR) and from the SIR Epidemiology Unit joined the working group and identified the key health questions on PMR to guide the systematic literature review. Physicians, including general practitioners and specialists, and health professionals who manage PMR in the clinical practice were the target audience. The final recommendations were rated externally by a multi-disciplinary and multi-professional group of stakeholders. From the systematic search in databases (Medline, Embase) and grey literature, 3 CPGs were identified and appraised by two independent raters. Combining the statements and the evidence from these CPGs, 9 recommendations were developed by endorsement or adaptation in response to the initial key health questions. The quality of evidence was graded and the working group discussed the final recommendations in view of their implementation in the Italian healthcare context. In absence of national guidelines so far, these recommendations are the first to provide guidance for the management of patients with a diagnosis of PMR in Italy and they are expected to ensure the best evidence-based clinical practice for this disease.
Identifiants
pubmed: 32292016
doi: 10.4081/reumatismo.2020.1268
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Glucocorticoids
0
Immunosuppressive Agents
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Practice Guideline
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-15Commentaires et corrections
Type : CommentIn
Type : CommentIn